Atorlip 40 Atorvastatin Tablets

Atorlip 40 Atorvastatin Tablets

203/Strip INR

Product Details:

  • Drug Type Specific Drug
  • Physical Form Tablets
  • Dosage 40 mg
  • Suitable For Adults
  • Supply Ability : 10000000 Piece Per Week
  • Click to view more
X

Price And Quantity

  • 10000000 Piece
  • 203/Strip INR

Product Specifications

  • 40 mg
  • Adults
  • Specific Drug
  • Tablets

Trade Information

  • Cash in Advance (CID), Cash Advance (CA)
  • 10000000 Piece Per Week
  • 1 Week
  • Africa, Middle East, Western Europe, Eastern Europe, South America, North America, Central America, Australia, Asia

Product Description

 Atorlip - Lipitor® (Atorlip calcium) is a synthetic lipid-lowering agent. Atorlip  is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis. In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age >/= 55 years, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Lipitor is indicated to: Reduce the risk of myocardial infarction Reduce the risk for revascularization procedures and angina Hypercholesterolemia Lipitor is indicated: as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (eg, LDL apheresis) or if such treatments are unavailable; as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains >/= 190 mg/dL or LDL-C remains >/= 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient Active ingredients: Atorvastatin

DHEER HEALTHCARE PRIVATE LIMITED

* Tips on getting accurate quotes. Please include product name, order quantity, usage, special requests if any in your inquiry.



DHEER HEALTHCARE PRIVATE LIMITED All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Ltd.